Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2010
08/19/2010US20100210604 Zwitterion solution for low-volume therapeutic delivery
08/19/2010US20100210603 Novel sulfonamide inhibitors of aspartyl protease
08/19/2010US20100210602 PhoU (PerF), A PERSISTENCE SWITCH INVOLVED IN PERSISTER FORMATION AND TOLERANCE TO MULTIPLE ANTIBIOTICS AND STRESSES AS A DRUG TARGET FOR PERSISTER BACTERIA
08/19/2010US20100210600 Methods and Compositions for Treating Urogenital Disorders
08/19/2010US20100210599 Prodrugs of piperazine and substituted piperidine antiviral agents
08/19/2010US20100210598 Toll-like receptor modulators and treatment of diseases
08/19/2010US20100210597 C21-Deoxy Ansamycin Derivatives as Antitumor Agents
08/19/2010US20100210596 Use of aminopyrimidine compounds in the treatment of immune disorders
08/19/2010US20100210595 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus
08/19/2010US20100210594 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus
08/19/2010US20100210593 Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
08/19/2010US20100210592 Amines or amino alcohols as glyt1 inhibitors
08/19/2010US20100210591 Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
08/19/2010US20100210590 Compositions and treatments for seizure-related disorders
08/19/2010US20100210589 Method for improving hepatic function
08/19/2010US20100210588 Hyaluronic Acid Linked with a Polymer of an Alpha Hydroxy Acid
08/19/2010US20100210586 Pomegranate extracts, nutritional products containing them and their uses
08/19/2010US20100210585 Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous
08/19/2010US20100210584 Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation
08/19/2010US20100210583 Novel antifolate combination therapies
08/19/2010US20100210582 Method and composition for treating patients with a high risk of developing neuro-immune disorders or developmental delays, identified through the utilization of low homocysteine or its precursors/metabolites, as the predictor of such risk
08/19/2010US20100210581 Nucleoside Derivatives as Inhibitors of Viral Polymerases
08/19/2010US20100210580 Vitamin B12 Nasal Spray and Method of Use
08/19/2010US20100210579 Partial and full agonists of a1 adenosine receptors
08/19/2010US20100210578 Prevention/Treatment of Ichthyosis Vulgaris, Atopy and Other Disorders
08/19/2010US20100210577 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
08/19/2010US20100210576 Polyene diester antibiotics
08/19/2010US20100210575 Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
08/19/2010US20100210574 Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4"-or 4'-position
08/19/2010US20100210573 Compound and compositions for treatment of disease
08/19/2010US20100210572 Hydrolysate of crocin
08/19/2010US20100210571 Topical formulations for treatment of skin disorders
08/19/2010US20100210570 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient
08/19/2010US20100210565 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
08/19/2010US20100210560 Neurotensin receptor agonists and opioid receptor agonists
08/19/2010US20100210542 Methods of Treating Disorders with Group I mGluR Antagonists
08/19/2010US20100210524 Novel estrogen receptor ligands
08/19/2010US20100210522 Method for determining presence of cancer in a sample by assaying for expression of dppa-2 nucleotide sequences
08/19/2010US20100210520 Regulation of function of angiopoietin
08/19/2010US20100210518 Peg-lipid conjugates for increasing the solubility of drug compounds
08/19/2010US20100210514 RNAi Inhibition of Alpha-ENaC Expression
08/19/2010US20100210513 RNAi Inhibition of Alpha-ENaC Expression
08/19/2010US20100210504 Enhanced transport using membrane disruptive agents
08/19/2010US20100210476 Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them
08/19/2010US20100209581 Food intermediate having sequestered phytosteryl esters in a polysaccharide matrix
08/19/2010US20100209543 Compositions and methods of use
08/19/2010US20100209542 Methods For Treating Withdrawal From Addictive Compounds
08/19/2010US20100209541 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
08/19/2010US20100209539 Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
08/19/2010US20100209538 Ph-modulated formulations for pulmonary delivery
08/19/2010US20100209537 Metal complexes with anticancer activity
08/19/2010US20100209536 Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases
08/19/2010US20100209529 Pharmacologic-functioning water and usage of the same
08/19/2010US20100209520 Oral pharmaceutical preparation for colon-specific delivery
08/19/2010US20100209517 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
08/19/2010US20100209516 Triggered Drug Release Via Physiologically Responsive Polymers
08/19/2010US20100209514 Method of treating pain by administering 24 hour oral oploid formulations exhibiting rapid rate of initial rise of plasma drug level
08/19/2010US20100209513 Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
08/19/2010US20100209511 sustained release pharmaceutical formulation
08/19/2010US20100209510 Extended Release Formulation and Method of Treating Adrenergic Dysregulation
08/19/2010US20100209508 Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction
08/19/2010US20100209507 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
08/19/2010US20100209506 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
08/19/2010US20100209505 Controlled release pharmaceutical formulations of nitazoxanide
08/19/2010US20100209504 Process for production of crystalline cellulose and tablets containing granules
08/19/2010US20100209501 Controlled release budesonide minitablets
08/19/2010US20100209500 Controlled release budesonide minitablets
08/19/2010US20100209499 Solid Oral Dosage Form Containing an Enhancer
08/19/2010US20100209498 Pharmaceutical compositions of duloxetine
08/19/2010US20100209497 Formulations for treating human and animal diseases
08/19/2010US20100209496 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
08/19/2010US20100209495 Granulates, process for preparing them and pharmaceutical products containing them
08/19/2010US20100209494 Liposomes and Uses Thereof
08/19/2010US20100209491 Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
08/19/2010US20100209489 Formulations of desvenlafaxine
08/19/2010US20100209488 Protein kinase modulating compounds and methods for making and using them
08/19/2010US20100209487 Nicked or gapped nucleic acid molecules and uses thereof
08/19/2010US20100209486 Method of enhancing CoenzymeQ10 levels in mammals
08/19/2010US20100209484 Transdermal Triptan Delivery System
08/19/2010US20100209483 Transdermal delivery of meptazinol
08/19/2010US20100209480 Galenical formulations of organic compounds
08/19/2010US20100209479 Compositions And Methods For Treating Cancer
08/19/2010US20100209478 Drug delivery through hydrogel plugs
08/19/2010US20100209477 Sustained release delivery of one or more agents
08/19/2010US20100209473 Intraluminal device with a coating containing a therapeutic agent
08/19/2010US20100209472 Drug releasing coatings for medical devices
08/19/2010US20100209469 Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
08/19/2010US20100209459 Alkaloid formulations
08/19/2010US20100209458 Amphiphilic molecule, molecular assembly comprising the amphiphilic molecule, and use of the molecular assembly
08/19/2010US20100209447 Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
08/19/2010US20100209441 Drug for suppressing pathogen occurring in vivo
08/19/2010US20100209436 Method for treating diseases related to mitochondrial dysfunction
08/19/2010US20100209431 Metal triangulo compound and methods of using the same
08/19/2010US20100209421 Targeting pax2 for the treatment of breast cancer
08/19/2010US20100209420 Methods of treating cancer using pyridopyrimidinone inhibitors of p13k alpha
08/19/2010US20100209419 Method and formulation for treating adverse biological conditions
08/19/2010US20100209418 Solid Forms of a Raf Kinase Inhibitor
08/19/2010US20100209415 Chemotherapeutic methods and compositions
08/19/2010US20100209407 Mc-1r, mc-2r, and/or mu opioid receptors modulation
08/19/2010US20100209401 Use of SDF-1 to Improve Ischemic Myocardial Function
1 ... 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 ... 7860